Skip to main content
CERo Therapeutics Holdings, Inc. (CERO)
NASDAQ: CERO · IEX Real-Time Price · USD
0.200
-0.043 (-17.66%)
Jul 19, 2024, 4:00 PM EDT - Market closed

CERO Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year Ending
 TTM Dec 31, 2023Dec 31, 2022Dec 31, 2021
Selling, General & Admin
-2.392.132.48
Research & Development
-5.299.859.14
Operating Expenses
-7.6811.9711.62
Operating Income
--7.68-11.97-11.62
Other Expense / Income
--0.39-0.14-0.99
Pretax Income
--7.29-11.83-10.63
Net Income
--7.29-11.83-10.63
Shares Outstanding (Basic)
12999
Shares Outstanding (Diluted)
-999
Shares Change
31.66%0.93%-0.08%-
EPS (Basic)
--0.80-1.32-1.18
EPS (Diluted)
--0.80-1.32-1.18
Free Cash Flow
--5.79-12.4-10.71
Free Cash Flow Per Share
--0.64-1.38-1.19
EBITDA
--6.17-10.76-9.89
Depreciation & Amortization
-1.121.070.74
EBIT
--7.29-11.83-10.63
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).